A prospective study on the safety of sublingual immunotherapy in pregnancy

Authors


  • Edited by: Thomas Bieber

Correspondence

Wiqar A. Shaikh, Department of Clinical Allergy and Asthma, Allergy and Asthma Clinic, Shakti Sadan, B BlockLamington Road, Bombay 400007, India.

Tel.: +9122/2308-8787

Fax: +91 22 23096007

E-mail: drwiqar@gmail.com

Abstract

Background

The aim of this study was to determine the safety of sublingual immunotherapy in pregnancy, which has not yet been reported.

Methods

One hundred and fifty-five patients received sublingual immunotherapy with either house dust mite (D. farinae) or a mixture of up to five allergens during 185 pregnancies. Twenty-four patients received sublingual immunotherapy for the first time during pregnancy. Follow-up data were analysed with regard to abortion, perinatal mortality, prematurity, toxaemia and congenital malformation. Two control groups did not receive immunotherapy; group A (85 patients) received budesonide 400 μg twice daily and group B (40 patients) received rescue salbutamol inhalation. All three groups were on appropriate avoidance measures.

Results

Six-year follow-up data for the sublingual immunotherapy group revealed an incidence of complications less than that in the general population and a higher incidence of complications in both control groups.

Conclusions

This study concludes that sublingual immunotherapy is safe during pregnancy and is also safe when initiated for the first time in a pregnant patient.

Ancillary